Are you living with non-small cell lung cancer (NSCLC) with a KRAS G12D mutation? You may be eligible to participate in a Phase III clinical research study evaluating an investigational treatment compared with docetaxel.

This study is for participants with locally advanced (unresectable) or metastatic NSCLC whose cancer has progressed during or after treatment with platinum-based chemotherapy and checkpoint inhibitor therapy.

If you are interested in learning more about this study and whether you may qualify, please contact our research team today.